Barclays PLC Analysts Give Sanofi SA (SAN) a €75.00 Price Target

Barclays PLC set a €75.00 ($82.42) target price on Sanofi SA (EPA:SAN) in a research report released on Monday, May 8th. The firm currently has a sell rating on the stock.

Several other research analysts have also commented on SAN. Sanford C. Bernstein set a €91.00 ($100.00) price target on Sanofi SA and gave the stock a neutral rating in a research report on Tuesday, May 2nd. Morgan Stanley set a €91.00 ($100.00) price objective on Sanofi SA and gave the company a buy rating in a research note on Wednesday, March 29th. JPMorgan Chase & Co. reiterated a sell rating on shares of Sanofi SA in a research note on Thursday, January 12th. Goldman Sachs Group Inc set a €81.00 ($89.01) price target on Sanofi SA and gave the company a neutral rating in a research note on Thursday, February 9th. Finally, Berenberg Bank set a €92.00 ($101.10) price target on Sanofi SA and gave the company a buy rating in a research note on Friday, April 28th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and four have issued a buy rating to the company’s stock. Sanofi SA currently has an average rating of Hold and an average target price of €86.44 ($94.99).

ILLEGAL ACTIVITY NOTICE: “Barclays PLC Analysts Give Sanofi SA (SAN) a €75.00 Price Target” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/05/19/sanofi-sa-san-given-a-75-00-price-target-at-barclays-plc-updated.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply